Mazdutide and Tirzepatide
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
Mazdutide and Tirzepatide are curated as a pair under Incretin receptor agonists. This page reads them across four axes at once: what each one is recorded as binding, what the molecule is, what shape its indexed record set has, and what the application register returned. Every cell is either a sourced value or a count of records.
A larger record count is not a better compound. Counts track how long a compound has been studied and how heavily it has been indexed, nothing else. Nothing on this page ranks the two.
Identity and target
| Axis | Mazdutide | Tirzepatide |
|---|---|---|
| Class as recorded | Incretin receptor agonists | Incretin receptor agonists |
| Receptor targets as recorded | GLP-1 receptor, Glucagon receptor | GIP receptor, GLP-1 receptor |
| Molecular formula | C207H317N45O65[6] | C225H348N48O68[14] |
| Molecular weight | 4476 g/mol[6] | 4813 g/mol[14] |
| CAS registry number | 2259884-03-0[6] | 2023788-19-2[14] |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
| Applications on the register | None on the query date[7] | 2 on the query date[15] |
Shape of the indexed record set
| Axis | Mazdutide | Tirzepatide |
|---|---|---|
| Records indexed here | 12 | 12 |
| Phase 3 records | 4 | 7 |
| Phase 2 records | 1 | 1 |
| Phase 1 records | 1 | 0 |
| Trial records with no phase assigned | 1 | 3 |
| Review or synthesis records | 4 | 0 |
| Records that are not registered trials | 1 | 1 |
| Study models as assigned | human trial 6; other 5; rodent 1 | human trial 10; other 2 |
| Publication years covered | 2025–2026 | 2024–2025 |
| Derived record-set tier | Human trial evidence | Human trial evidence |
| Basis of that tier | 6 of 12 indexed records are interventional human trials by their own assigned publication type | 10 of 12 indexed records are interventional human trials by their own assigned publication type |
| Review state | Pending qualified review | Pending qualified review |
The derived tier counts record types. It is not an assessment of clinical efficacy, of safety, of study quality or of consensus, and the two tiers on this row are not a verdict about which compound is better supported.
Endpoint coverage, side by side
| Axis | Mazdutide | Tirzepatide |
|---|---|---|
| Body weight and adiposity | 11 | 9 |
| Glycaemic control | 9 | 3 |
| Cardiovascular | 0 | 6 |
| Renal | 0 | 0 |
| Hepatic | 0 | 1 |
| Neurological | 1 | 0 |
Each endpoint is defined by a fixed set of subject headings, printed in full on the endpoint pages.
Which axes diverge
16 of the 23 axes above differ between the two, 6 carry the same value, and 1 are unsourced on both sides. A divergence is a difference in what the corpus records, not a difference in what either compound does.
| Result | Axes |
|---|---|
| Differ | Receptor targets; Molecular formula; Molecular weight; CAS registry number; Applications on the register; Phase 3 records; Phase 1 records; Unphased trial records; Review records; Study models; Publication years; Body weight and adiposity records; Glycaemic control records; Cardiovascular records; Hepatic records; Neurological records |
| Same value | Class as recorded; Records indexed; Phase 2 records; Non-trial records; Derived record-set tier; Renal records |
| Unsourced on both sides | Reported half-life |
The corpus also carries a curated divergence note for this pair, written for the reference layer rather than for this one. It is not reproduced here; the records behind it are cited[1, 2, 3, 4, 5] and listed in the sources below.
Records indexed under both
No record in this corpus is indexed under both compounds. That is the absence of a retrieved head-to-head record in this selection, not evidence that none exists.
Where this page sits
- Mazdutide: the full indexed record set
- Tirzepatide: the full indexed record set
- Every curated pair in this class
Sources
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine (2022). pmid:36247927
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. The New England journal of medicine (2025). pmid:40421736
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature (2026). pmid:41407860
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (2021). pmid:34186022
- Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med (2022). pmid:35658024
- PubChem Compound Summary for CID 167312357, Mazdutide. PubChem, National Library of Medicine (2026). pubchem:167312357
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:mazdutide
- IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine (2021). pmid:34430840
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature communications (2022). pmid:35750681
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature communications (2023). pmid:38092790
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes care (2024). pmid:37943529
- Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature (2026). pmid:41407859
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Frontiers in endocrinology (2024). pmid:38440786
- PubChem Compound Summary for CID 166567236, tirzepatide. PubChem, National Library of Medicine (2026). pubchem:166567236
- Drugs@FDA application register query for this compound, 2 application(s) returned: NDA215866, NDA217806. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tirzepatide
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med (2024). pmid:38856224
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med (2025). pmid:39555826